FluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults

  • Study will measure immune responses generated by M2SR and high dose vaccine separately and in combination in the highly vulnerable 65-85 years old population
  • Funded by the US Department of Defense, this study is expected to yield topline data in 2H 2022



MADISON, Wis., June 22, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the dosing of its first subject in an unprecedented study of older adults ages 65-85 years. The study will evaluate the safety, tolerability, and immunological response to FluGen’s investigational supra-seasonal, live, single-replication, intranasal M2SR influenza (flu) vaccine, and high dose inactivated vaccine (IIV).

There is a demonstrated unmet need for improved flu vaccine options, as current injectable vaccines primarily generate hemagglutinin (HA) antibodies and have shown only modest efficacy in most flu seasons. Funded by the U.S. Department of Defense (DOD), this study will evaluate M2SR and high dose IIV alone, and dosed concomitantly, in healthy adults 65-85 years of age, a population considered highly vulnerable to mortality from flu.